ACRS - NASDAQ
Aclaris Therapeutics, Inc.
$4.42
-4.5%Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
At a Glance
Live SnapshotAclaris Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Aclaris Therapeutics, Inc. Cash Flow Statement
ACRS • NASDAQ
| Aclaris Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-64.9M | -132.1M | -88.5M | -86.9M | -90.9M | -51M | -161.4M | -132.7M | -68.5M | -48.1M | -20.6M | -8.5M | -5.2M | |
454K | 807K | 863K | 797K | 923K | 1.3M | 6.4M | 1.9M | 402K | 120K | 90K | 12K | 11K | |
0.0 | 0.0 | -367K | 0.0 | 752K | -182K | 44.3M | 0.0 | -1.8M | 216K | 289K | 0.0 | 0.0 | |
12.4M | 10.9M | 20.5M | 15M | 14.1M | 11.2M | 16.2M | 20.1M | 14.4M | 6.1M | 891K | 27K | 0.0 | |
2.3M | 89.4M | -20.3M | 4.7M | 24.3M | 2.4M | 734K | 555K | 10.7M | 2.8M | -5K | 1K | 3K | |
2.7M | 10.9M | 9.4M | -1.2M | -1.3M | -2.4M | -2.7M | 9.4M | 865K | 4.3M | -1.1M | 841K | 302K | |
-47.1M | -20.1M | -78.3M | -67.6M | -52.1M | -38.6M | -96.4M | -100.8M | -54.7M | -34.6M | -20.4M | -7.6M | -4.9M | |
INVESTING ACTIVITIES | |||||||||||||
-111K | -121K | -1.3M | -605K | -308K | -453K | -1.6M | -1.4M | -1.2M | -232K | -507K | -417K | (0.0) | |
(0.0) | (0.0) | (0.0) | -13.2M | (167.3M) | (0.0) | (34.2M) | -67.1M | -9.6M | (0.0) | (0.0) | (0.0) | (0.0) | |
-39.7M | -120M | -135.7M | -164.8M | -235.2M | -47.7M | -137.4M | -161.6M | -197.3M | -148.8M | -82.5M | -5M | -4.5M | |
89M | 86.1M | 183.2M | 178M | 67.8M | 54.6M | 210.5M | 239.4M | 152.5M | 87.1M | 6.1M | 3.7M | 0.0 | |
-833K | -35.8M | 0.0 | 13.2M | -167.3M | 0.0 | 0.0 | 77.8M | -44.8M | -61.7M | -76.4M | -1.4M | -4.5M | |
(48.4M) | -69.8M | (46.2M) | (12.6M) | -167.6M | (6.4M) | (105.7M) | (9.4M) | -55.7M | -61.9M | -77M | -1.8M | -4.5M | |
FINANCING ACTIVITIES | |||||||||||||
0.0 | 74.9M | 26.7M | 72.7M | 238.2M | 7.7M | 0.0 | 100.2M | 100.2M | 116.7M | 56.6M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -11.5M | 10.8M | -30.5M | 29.3M | -78K | 0.0 | 0.0 | 0.0 | 0.0 | |
-5.9M | -377K | -8K | 123K | -1.7M | -141K | 207K | -1.2M | 235K | 121K | 0.0 | 0.0 | 0.0 | |
-5.9M | 74.5M | 26.7M | 72.9M | 225.1M | 18.4M | -30.3M | 128.3M | 100.4M | 116.8M | 96.4M | 10.6M | 0.0 | |
CASH FLOW SUMMARY | |||||||||||||
-4.6M | -15.3M | -5.4M | 17.9M | 5.3M | -13.9M | -21.1M | 36.8M | -10M | 20.3M | -906K | 1.2M | -9.5M | |
24.6M | 39.9M | 45.3M | 27.3M | 22.1M | 35.9M | 57M | 20.2M | 30.2M | 9.9M | 10.8M | 9.6M | 19M | |
20M | 24.6M | 39.9M | 45.3M | 27.3M | 22.1M | 35.9M | 57M | 20.2M | 30.2M | 9.9M | 10.8M | 9.6M | |
-47.1M | -20.2M | -79.6M | -68.2M | -52.4M | -39.1M | -98.1M | -102.2M | -55.9M | -34.8M | -20.9M | -8.1M | -4.9M |
SEC Filings
ACRS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 |
Related Guides
Continue your ACRS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.